OTTAWA, April 18 /CNW/ - Canada's Research-Based Pharmaceutical
Companies (Rx&D) President, Russell Williams, is pleased to welcome a
new member to the association representing the innovative
pharmaceutical industry in Canada.
Sepracor Pharmaceuticals, Inc. (Sepracor), based in Mississauga,
Ontario, has joined Rx&D as a full member.
Sepracor, a division of Sunovion Pharmaceuticals Inc., is dedicated to
the commercialization of prescription pharmaceutical products in Canada
with a specific focus in the cardiovascular and central nervous system
"We are pleased to be joining Rx&D. The values and interests of the
association reflect those of companies like ours, and Sepracor is
excited to be part of this industry association," said Douglas
Reynolds, Sepracor's President.
"The value and benefits of becoming an Rx&D member company are clearly
being recognized by a growing list of companies in Canada's life
sciences sector. We look forward to working with Sepracor
Pharmaceuticals, Inc. as we continue to build the capacity of the life
science sector in Canada," said Rx&D President Russell Williams.
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information:
Mike Murphy, Communications